Methods, compositions, and kits useful for reducing pigmentation or treating hyperpigmentation disorders are disclosed. In accordance with the present disclosure, BET bromodomain protein inhibitors, such as JQ1, are used to reduce pigmentation, promote cell cycle arrest, inhibit the expression of TYR, TRP1, and DCT proteins, inhibit the expression of TYR mRNA, and suppress melanocyte proliferation.
